Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Psychometric Validation of the Autism Impact Measure (AIM).
Houghton R, Monz B, Law K, Loss G, Le Scouiller S, de Vries F, Willgoss T. Houghton R, et al. Among authors: le scouiller s. J Autism Dev Disord. 2019 Jun;49(6):2559-2570. doi: 10.1007/s10803-019-04011-2. J Autism Dev Disord. 2019. PMID: 30968318 Free PMC article.
Psychometric evaluation of the Work Readiness Questionnaire in schizophrenia.
Potkin SG, Bugarski-Kirola D, Edgar CJ, Soliman S, Le Scouiller S, Kunovac J, Miguel Velasco E, Garibaldi GM. Potkin SG, et al. Among authors: le scouiller s. CNS Spectr. 2016 Apr;21(2):199-206. doi: 10.1017/S1092852914000352. Epub 2014 Oct 1. CNS Spectr. 2016. PMID: 25269787 Free PMC article.
Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
Edgar CJ, Blaettler T, Bugarski-Kirola D, Le Scouiller S, Garibaldi GM, Marder SR. Edgar CJ, et al. Among authors: le scouiller s. Psychiatry Res. 2014 Aug 15;218(1-2):219-24. doi: 10.1016/j.psychres.2014.04.009. Epub 2014 Apr 13. Psychiatry Res. 2014. PMID: 24809242 Clinical Trial.
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Trarbach T, Schultheis B, Gauler TC, Schneider V, Strumberg D, Eberhardt WE, Le Scouiller S, Marotti M, Brown KH, Drevs J. Trarbach T, et al. Among authors: le scouiller s. Invest New Drugs. 2012 Oct;30(5):1962-71. doi: 10.1007/s10637-011-9754-x. Epub 2011 Oct 12. Invest New Drugs. 2012. PMID: 21989836 Clinical Trial.
11 results